| Indication | Ebola virus infection |
| Drug | rVSV-EBOV vaccine |
| Mechanism of Action | Recombinant VSV-based vaccine |
| Company | Merck |
| Trial Phase | Phase I |
| Category | Corporate & Strategic |
| Sub Category | Licensing Agreement |
| Therapeutic Area | Infectious Diseases & Vaccines |
| Agreement Type | Exclusive Worldwide License Agreement |
| Licensor Company | NewLink Genetics Corporation |
| Original Vaccine Developer | Public Health Agency of Canada (PHAC) |
| Planned Trial Phase | Phase III |
| Planned Phase III Start | early 2015 |
| Phase I Study Sites | Walter Reed Army Institute of Research, NIAID at NIH, Switzerland, Germany, Kenya, Gabon, Canada |
| Announcement Date | November 24, 2014 |
| Funding Source | CBRN Research and Technology Initiative |
Merck and NewLink Genetics Partner for Investigational Ebola Vaccine Development
Merck and NewLink Genetics Corporation have announced an exclusive worldwide licensing and collaboration agreement for NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate. This vaccine, originally developed by the Public Health Agency of Canada, is currently undergoing Phase I clinical trials. The agreement grants Merck exclusive rights to research, develop, manufacture, and distribute the vaccine globally. Pending Phase I results, the U.S. National Institutes of Health (NIH) plans to initiate a large randomized, controlled Phase III study in early 2015 to evaluate the vaccine's safety and efficacy. This partnership aims to leverage Merck's vaccine expertise to address the urgent global health priority of Ebola prevention and control.
- Merck has secured exclusive worldwide rights from NewLink Genetics for the rVSV-EBOV vaccine candidate, covering its research, development, manufacturing, and distribution. This collaboration combines NewLink's innovative asset with Merck's extensive vaccine development expertise and commercial leadership to accelerate the vaccine's availability globally.
- The rVSV-EBOV vaccine was initially developed by scientists at the Public Health Agency of Canada's National Microbiology Laboratory, with significant funding from the CBRN Research and Technology Initiative. NewLink Genetics, through its subsidiary BioProtection Systems, held the sole license and has been instrumental in producing clinical trial materials and advancing the vaccine into Phase I studies.
- The vaccine is currently in Phase I clinical trials at multiple sites, including the Walter Reed Army Institute of Research and NIAID at NIH, with additional studies underway or planned in Switzerland, Germany, Kenya, Gabon, and Canada. Following these Phase I results, the U.S. NIH intends to launch a large randomized, controlled Phase III study in early 2015 to evaluate the vaccine's safety and efficacy.
Merck's Strategic Focus on Ebola's Unmet Needs
Recent literature highlights sustained focus on durable prophylactic protection for groups at recurrent risk of Ebola virus disease, alongside strategies for booster and post-exposure use. Research targets health-care and front-line workers, children, people living with HIV, women, and previously vaccinated contacts facing re-exposure.
Health-care providers and front-line workers in endemic areas: An open-label, randomised, phase 2 trial at one study site within a hospital in Boende, Democratic Republic of the Congo, assessed long-term immunogenicity of the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen and safety and immune memory response to an Ad26.ZEBOV booster vaccination at 1 year or 2 years after the first dose in adult health-care providers and front-line workers.
Children as a high-burden paediatric population: An open-label, non-randomised, phase 2 trial at one clinic in Kambia Town, Sierra Leone, evaluated safety and immunogenicity of an Ad26.ZEBOV booster dose in children who had received the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen, and five-year follow-up of the PREVAC randomized Trial assessed persistence of vaccine-induced immune responses in adults and children aged ≥ 1 year.
People living with HIV in at-risk regions: A single-arm, open-label Phase II clinical trial in Kenya and Uganda assessed Ad26.ZEBOV booster safety and antibody responses against the Ebola virus glycoprotein in HIV+ adults with well-controlled infection and on highly active antiretroviral therapy who had previously received the Ad26.ZEBOV, MVA-BN-Filo primary regimen.
Women in North Kivu and Ituri: Research describes women as more susceptible during outbreaks due to frontline caregiving roles, domestic and community duties including washing and dressing the deceased, agricultural work and market activity, reduced access to information, and lowered access to health services including gynecological assistance, particularly during pregnancy.
Previously vaccinated individuals needing revaccination guidance: With the number of individuals vaccinated against EBOV worldwide estimated to range between 500 000 and 1 000 000 individuals, priority gaps include to whom, when, and how frequently to provide booster doses, long-term correlates and thresholds of protection, effect of vector-directed immunity and viral variant protection, comparative research in mix-and-match schedules, and implementation concerns.
High-risk contacts requiring post-exposure prophylaxis: Narrative review and Viewpoint literature evaluates rVSVΔG-ZEBOV-GP vaccine and monoclonal antibodies mAb114 and REGN-EB3 for post-exposure prophylaxis following high-risk exposure, highlighting need for emergency stockpile of monoclonal antibodies, improved contact tracing, and optimized risk assessment criteria.
Assessing the Safety Profile of the rVSV-EBOV Vaccine
Across phase 1, phase 2/3, ring vaccination, emergency deployment and postexposure settings, rVSV-ZEBOV (rVSVΔG-ZEBOV-GP, V920, Ervebo®) was safe and well tolerated with no consistent signal of vaccine-related serious adverse events. Early reactogenicity was frequent but typically mild to moderate, transient and self-limited, while delayed oligoarthritis, rash/dermatitis and vasculitis occurred at low incidence in the second week.
Early reactogenicity and viremia: Many vaccinees experience a mild acute-phase reaction with fever, headache, myalgia, arthralgia, fatigue and injection site pain of short duration during the first few days after vaccination; this period is associated with a low-level viremia, activation of anti-viral genes, and increased levels of chemokines and cytokines. In Geneva frontline workers receiving a single injection of rVSV-ZEBOV (>7.2E7 plaque forming unit), 105/109 (96.3%) experienced at least one AE with a mean of three (±SD 1.75) AEs per person, most commonly injection site pain, followed by fever (53/109; 48.6%), fatigue (51/109; 46.7%) and myalgia (49/109; 44.9%), with 360/377 (95.4%) of early AEs resolving within 3 days. In a phase 1, randomized, dose-ranging, observer-blind, placebo-controlled trial, solicited adverse events during the 14-day follow-up period were mild to moderate and self-limited, with the exception of injection-site pain and headache, viremia was transient and no longer detectable after study day 3, with no virus shedding in saliva or urine. In the Guinea ring vaccination trial, 3149 (53.9%) of 5837 individuals reported at least one adverse event in the 14 days after vaccination, typically mild (87.5% of all 7211 adverse events), most commonly headache (1832 [25.4%]), fatigue (1361 [18.9%]), and muscle pain (942 [13.1%]).
Dose effect on tolerability: At 3×10(5) pfu, early-onset reactogenicity remained frequent (45 [88%] of 51 compared with 50 [98%] of 51 high dose and two [15%] of 13 placebo recipients), but mild, with objective fever in one (2%) of 51 low-dose versus 13 (25%) of 51 high-dose vaccinees receiving at least 1×10(7) pfu (p<0·0001), and significantly reduced subjective fever (p<0·0001), myalgia (p=0·036), and chills (p=0·026) with delayed onset, reflecting significantly lower viraemia (p<0·0001) and blood monocyte-activation patterns (p=0·0233). Reducing the dose of rVSV-ZEBOV improved its early tolerability but lowered antibody responses and did not prevent vaccine-induced arthritis, dermatitis, or vasculitis.
Delayed arthritis, dermatitis, rash and vasculitis: Oligoarthritis and rash appearing in the second week occur at a low incidence, and are typically mild-moderate in severity and self-limited. After viral oligoarthritis was observed in 11 of the first 51 vaccinees (22%) receiving 10(7) or 5×10(7) pfu, oligoarthritis again occurred on day 10 (median; IQR 9-14) in 13 (25%) of 51 low-dose vaccinees, with maculopapular, vesicular dermatitis, or both in seven (54%) of 13; arthritis was associated with increasing age in low-dose but not high-dose vaccinees. Two vaccinees presented with purpura of the lower legs; histological findings indicated cutaneous vasculitis, with presence of rVSV in synovial fluid and skin lesions confirming causality. In frontline workers, delayed AEs were reported by 6/69 (7.2%) subjects, median time to symptom onset was 11 days (range: 5-14); half were joint-related AEs (3/6). Postexposure follow-up reported common fatigue, myalgia, headache, arthralgia, and fever, with a high percentage developing fever ≥37.5°C and a small number developing persistent arthralgia.
Serious adverse events: No serious adverse events related to the vaccine or participant withdrawals were reported in early phase 1 studies, and no vaccine-related serious adverse events, which by regulatory definition include death, life-threatening illness, hospitalization or prolongation of hospitalization, or permanent disability, were reported in STRIVE (8,673 participants) as of April 28, 2016. In the final Guinea ring analysis, 80 serious adverse events were identified, of which two were judged to be related to vaccination (one febrile reaction and one anaphylaxis) and one possibly related (influenza-like illness); all three recovered without sequelae. In frontline workers, four serious adverse events were observed: two cases of high grade fever, one rash and one case of arthritis, plus one case of continuing recurrent transient dizziness and fatigue considered related to the vaccine and one case of presbyopia deemed unrelated. No severe vaccine-related adverse events were reported after postexposure prophylaxis, and no toxicities occurred after intramuscular (IM) or intracranial injection of nonhuman primates and no reproductive or developmental toxicity in a rat model.
Safety in children and pre-existing immunity: In 5837 individuals receiving vaccine including 194 children, adverse event patterns were reported across all age groups with the same leading events. Vaccinees with baseline IgG antibodies against Zaire Ebolavirus had similar safety profiles to those without detectable antibodies (63.6% vs 66.1% adults experienced any adverse event; 49.1% vs 60.9% in children), with almost all adverse events graded as mild and no serious adverse events attributed to vaccination.
Overcoming Current Challenges in Ebola Virus Infection Treatment
Despite the approval of REGN-EB3 and mAb114, mortality in the PALM study accounted for 30% despite the administration of specific treatments, and treatment with RDV, mAb114, REGN-EB3, and ZMapp each resulted in similar survival (approximately 40%) in a uniformly lethal rhesus monkey model of EVD. Only two RCTs with a total of 753 patients proved eligible for network meta-analysis, and very few studies have been conducted specifically to determine the efficacy of vaccines or monoclonal antibodies as post-exposure prophylaxis.
Advanced disease reduces therapeutic benefit. A shorter duration of symptoms before admission and lower baseline values for viral load and for serum creatinine and aminotransferase levels each correlated with improved survival, while survival was associated with circulating viral load at treatment initiation and delaying care and treatment at EVD treatment centres increased mortality risk by 5% for each day following symptom onset.
Viral escape and decoy mechanisms threaten durability. The viral mutation escape, leading to resistance, presents a potential limitation for single mAb therapy, a trend of more escape mutants in the GP1 and GP2 domains was observed for the mAb114 group, epitope mutations might reduce efficacy, and the putative role of EBOV soluble Glycoprotein (sGP) as a decoy to the immune system, the virus persistence, and relapses might be investigated for treatment failure.
Effects on endogenous immunity and long-term outcomes remain unresolved. Monoclonal antibodies might negatively affect the production of anti-Ebola virus antibodies in survivors of Ebola virus disease which could increase the risk of reinfection or reactivation, 85 (24%) of 358 were seronegative for at least two Ebola virus antigens on discharge from the Ebola treatment centre, and neurologic sequelae were more frequent in the REGN-EB3 group (hazard ratio, 2.14; 95% CI, 1.28-3.57) as compared with the remdesivir group while musculoskeletal sequelae were associated with ZMapp treatment (3.17; 1.81-5.56).
Critical knowledge gaps for combination use, special populations, and access persist. Understanding the contribution of Fc-mediated antibody functions such as antibody-dependent cellular cytotoxicity (ADCC) of those approved mAbs is still critical, the impact of early administration of Ebola-specific mAbs on developing a robust immune response for future Ebola virus exposure is unknown, the interaction between FDA-approved mAbs and vaccines remains unclear and needs to be investigated, and scientists should focus on developing more economic therapeutics.
Frequently Asked Questions
References
- [1] Kikwango EM, Akilimali PZ et al.. Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo. Virology journal. 2025 May 15. 40375337
- [2] Moekotte AL, Huson MA et al.. Monoclonal antibodies for the treatment of Ebola virus disease. Expert opinion on investigational drugs. 2016 Nov. 27676206
- [3] Sivanandy P, Jun PH et al.. A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. Journal of infection and public health. 2022 Mar. 35085865
- [4] Letafati A, Salahi Ardekani O et al.. Ebola virus disease: A narrative review. Microbial pathogenesis. 2023 Aug. 37355146
- [5] Potet J, Adjaho I et al.. [Post-exposure prophylaxis against Ebola virus: arguments for expanding the role of monoclonal antibodies in a context of limited access]. Medecine tropicale et sante internationale. 2026 Mar 31. 42221441
- [6] Tapia MD, Sow SO et al.. Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. The Lancet. Infectious diseases. 2020 Jun. 32199492
- [7] Onyeneho NG, Aronu NI et al.. The Impact of the Ebola Virus Disease Epidemic among Women in the Provinces of North Kivu and Ituri in the Democratic Republic of the Congo. Journal of immunological sciences. 2023 May 12. 38333354
- [8] Chandrasekaran P, Berry IM et al.. Vector-Induced Humoral Responses After rVSVΔG-ZEBOV-GP Immunization Identify Vaccinated Individuals and Correlate With Ebola Virus Glycoprotein Antibodies. The Journal of infectious diseases. 2025 Oct 15. 39718991
- [9] Nkuba-Ndaye A, Dilu-Keti A et al.. Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study. The Lancet. Infectious diseases. 2024 Mar. 38043556
- [10] Huttner A, Combescure C et al.. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Science translational medicine. 2017 Apr 12. 28404856
- [11] Ottoni MP, Ricciardone JD et al.. Ebola-negative neonates born to Ebola-infected mothers after monoclonal antibody therapy: a case series. The Lancet. Child & adolescent health. 2020 Dec. 33217357
- [12] Gao Y, Zhao Y et al.. Effects of therapies for Ebola virus disease: a systematic review and network meta-analysis. The Lancet. Microbe. 2022 Sep. 35803293
- [13] Harrison-Williams L, Vandy MJ et al.. Establishing Vitreoretinal Surgery Capacity in Sierra Leone: Challenges and Opportunities to Address Retinal Health Disparities in Resource-limited Settings. International ophthalmology clinics. 2024 Oct 1. 39480206
- [14] Manno D, Bangura A et al.. Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial. The Lancet. Infectious diseases. 2023 Mar. 36273490
- [15] Dahlke C, Kasonta R et al.. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine. 2017 May. 28434944
- [16] Monath TP, Fast PE et al.. rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment. Vaccine: X. 2019 Apr 11. 31384731
- [17] Henao-Restrepo AM, Longini IM et al.. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet (London, England). 2015 Aug 29. 26248676
- [18] Mbala-Kingebeni P, Aziza A et al.. Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: a rapid genomic assessment. The Lancet. Infectious diseases. 2019 Jun. 31000464
- [19] Kasereka MC, Mumtaz Z et al.. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine. Drugs of today (Barcelona, Spain : 1998). 2021 Jan. 33594388
- [20] Kallay R, Muhoza P et al.. Perceptions of factors influencing Ebola vaccine acceptance among community members, healthcare workers, and response personnel in Eastern Democratic Republic of the Congo. PloS one. 2026. 41945571
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com












